Sugi Predict

Sugi Predict / Compounds / SCHEMBL1397149

SCHEMBL1397149

SCHEMBL1397149

C=Cc1ccccc1OCC(=O)OC1C=CC=CO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ALDH1A1 P00352 5/20 0.37
▸ HPGD P15428 4/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ LMNA P02545 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ S1PR4 O95977 1/20 0.37
▸ ITGA4 P13612 1/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TLR9 Q9NR96 1/20 0.37
▸ MMP2 P08253 1/20 0.35
▸ MMP3 P08254 1/20 0.35
▸ MMP13 P45452 1/20 0.35
▸ MMP14 P50281 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2305216 0.76 ALDH1A1 (0.32) ALDH1A1
SCHEMBL1397197 0.74 PTGDR2 (0.47) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2
SCHEMBL1397119 0.71 USP2 (0.47) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2
SCHEMBL1397178 0.71 PTGDR2 (0.40) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2
SCHEMBL3364010 0.71 USP2 (0.39) PTGDR2USP2ALDH1A1LMNAMAPT
SCHEMBL6687183 0.70 PTGDR2 (0.72) PTGDR2ALDH1A1HPGDSMN1; SMN2MAPK1
SCHEMBL28555380 0.70 ALDH1A1 (0.38) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2
SCHEMBL10627483 0.69 PTGDR2 (0.51) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2
SCHEMBL17863711 0.69 PTGDR2 (0.51) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2
SCHEMBL2197295 0.68 CYP19A1 (0.46) PTGDR2USP2ALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595182-B1 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2015-09-30 — — EP disclosed
EP-2349993-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-08-03 — — EP disclosed
EP-2288599-A1 SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2011-03-02 — — EP disclosed
WO-2010046240-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2010-04-29 — — WO disclosed
WO-2009150074-A1 SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2009-12-17 — — WO disclosed
EP-2030081-A2 OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS Ciba Holding Inc. (CH) 2009-03-04 — — EP disclosed
US-7399577-B2 Halogenated oxime derivatives and the use thereof CIBA SPECIALTY CHEMICALS CORPORATION (US) 2008-07-15 — — US disclosed
WO-2007147782-A2 OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS CIBA HOLDING INC. (CH) 2007-12-27 — — WO disclosed
US-20060246377-A1 Halogenated oxime derivatives and the use thereof as latent acids BASF SE (DE) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246377-A1 Halogenated oxime derivatives and the use thereof as latent acids AHR, ARSA, SULT1A1 PTGDR2 3307/4885USP2 3782/4885ALDH1A1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.